molecules of the month


oral THR agonist prodrug

positive Ph. II data in NASH

thyroid hormone mimetic prodrug

Clinical data release, May 16, 2023

Metabasis, CA / Viking Therapeutics, CA

VK2809, THR-beta, oral THR agonist prodrug positive Ph. II data in NASH, thyroid hormone mimetic prodrug, Clinical data release, May 16, 2023, METABASIS, CA / VIKING THERAPEUTICS, CA
7 mins read

A potential best-in-class TRβ agonist prodrug for NASH demonstrates impressive efficacy and safety. Thyroid hormone receptor β (TRβ, THRβ or THR-β) agonists have seen a surge of interest in non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), largely thanks to impressive Ph. III clinical data from resmetirom, a Breakthrough Therapy and 2022 Molecule of the Year candidate developed by Madrigal and originated at Roche. If its recently accepted NDA is approved, resmetirom could become the first drug to achieve accelerated approval for NASH after decades of research effort. Based on recent Ph. IIb results, Viking Therapeutics believes its liver-targeted TRβ agonist prodrug, VK2809 (MB07811, from Metabasis), could be best-in-class. In the trial, 85% of participants experienced 30% or greater…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: